Clinical Trials

Exploration of WEE-1 Inhibition in Recurrent/Persistent Uterine Serous Carcinoma Continues to Phase 2

August 4th 2021

Following the success of a phase 1 study that showed its potential for accelerated FDA approval in the future, the WEE-1 inhibitor, ZN-c3 has been dosed for the first time in the newly launched phase 2 study, which is exploring the agent for the treatment of adult women with recurrent or persistent uterine serous carcinoma.

Trial Aims to Determine Efficacy of Radiotherapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER+ Breast Cancer With LMD

August 4th 2021

In an interview with Targeted Oncology™, Kamran A. Ahmed, MD, discussed the novel treatment strategy of combining radiotherapy with intrathecal trastuzumab/pertuzumab as well as and the rationale behind the combination.

Impact on Survival of Durvalumab +/- Olaparib Investigated in Endometrial Cancer

July 30th 2021

In an interview with Targeted Oncology™, Shannon N. Westin, MD, MPH, FACOG, discussed the DUO-E trial, its design, end points, and the need for novel endometrial cancer therapies. 

FDA Warns of Death Risk in Ongoing Multiple Myeloma Clinical Trial

July 29th 2021

A warning from the FDA highlights that an increased rate of death has been observed in patients with multiple myeloma who are undergoing treatment with the FDA-approved agent melphalan flufenamide in combination with dexamethasone in the phase 2 OCEAN clinical trial.

Study Evaluates Addition of Selinexor to Ruxolitinib in Patients With Treatment-Naïve Myelofibrosis

July 29th 2021

Selinexor has been administered in combination with ruxolitinib to the first patient with treatment-naïve myelofibrosis as part of a phase 1/2 clinical trial.

Study Explores Anti-PVRIG Therapy Plus Nivolumab and Anti-TIGIT Therapy in Advanced Solid Tumors

July 28th 2021

The first patient with an advanced solid tumor has been dosed with the first-in-class anti-PVRIG antibody, COM701, in combination with nivolumab and the anti-TIGIT antibody, BMS-986207, in a phase 1/2 clinical trial.

Oral MDM2 Inhibitor Milademetan Enters Phase 3 Study for Patients with De-Differentiated Liposarcoma

July 22nd 2021

A phase 3 study has been initiated in order to evaluate the efficacy of the oral MDM2 inhibitor milademetan for the treatment of de-differentiated liposarcoma.

First Patient Dosed in LAVA-051 Hematologic Malignancy Trial

July 19th 2021

The first patient has been dosed in the phase 1/2a clinical trial, designed to evaluate LAVA-051- a gamma-delta bispecific gamma-delta T cell engager that activates Vγ9Vδ2 T cells and type 1 natural killer T cells-in those with chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia.

Clinical Trial of Seclidemstat for Ewing Sarcoma Adds Fox Chase Cancer Center to List of Treatment Sites

July 19th 2021

The Fox Chase Cancer Center at Temple University in Philadelphia, Pennsylvania has been added as an active trial site by Salarius Pharmaceuticals, Inc. for the ongoing trial of seclidemstat for the treatment of relapsed or refractory Ewing sarcoma and advanced FET-rearranged sarcomas.

Dual Blockade of PVRIG and TIGIT Underway in Patients With Advanced Malignancies

July 15th 2021

The investigational anti-TIGIT agent, COM902, has been administered to a patient for the first time as part of a phase 1 clinical trial evaluating COM902 in combination with the anti-PVRIG agent, COM701 in patients with advanced malignancies who have no alternative treatment options.

TiTAN-1 Trial of GEN-011 Initiates Treatment in Patients With Solid Tumors

July 13th 2021

The first patient with a solid tumor has been dosed in the TiTAN-1 clinical trial, which is aiming to determine the safety, tolerability, and efficacy of GEN-011, a next-generation neoantigen adoptive cell therapy.

BTX-A51 Treatment Initiated in Advanced Solid Tumor Malignancies

June 10th 2021

The first patient with an advanced solid tumor has been dosed in a phase 1 clinical trial of the multi-kinase inhibitor BTX-A51.

Novel CDK4/6 ARK5 Inhibitor Explored as a Treatment for Advanced Cancers

May 26th 2021

The investigational CDK4/6 ARK5 inhibitor, ON 123300, has been dosed in the first time in a patient whose is enrolled in a phase 1 trial of ON 123300 for the treatment of advanced cancers.

Safety/Feasibility of CAR T-Cell Therapy Being Investigated in Brain Tumors

May 18th 2021

The first patient has been dosed in a study designed to evaluate the safety and feasibility of IL13Rα2 chimeric antigen receptor T cell therapy for the treatment of leptomeningeal brain tumors, such as glioblastoma, ependymoma, and medulloblastoma.

Phase 3 Study of Imtelstat Versus BAT Explores Survival Improvement in Myelofibrosis

April 15th 2021

A phase 3 study with the goal of demonstrating overall survival benefit with imetelstat versus best available therapy in patients with refractory myelofibrosis has dosed the first patient with the experimental agent.

Study of CRX100 Makes Progress in Patients With Refractory Solid Tumors

March 5th 2021

The novel combined immunotherapy CRX100 has been dosed in the first patient with refractory solid tumors in a phase 1, open-label, dose-escalation study.

Novel T-Cell Based Immunotherapy Dosed Phase 2 Study of Patients With AML

March 3rd 2021

The first patient with acute myeloid leukemia in a phase 2 trial of the MultiTAA-specific T cell, MT-401 followed stem-cell transplant has been dosed with the agent, according to a press release by Marker Therapeutics, Inc.

MYC-Targeted Agent Dosed in First Patient in Early-Phase Solid Tumor Study

February 26th 2021

The first patient has been dosed in the phase 1/2 clinical trial of an oral CDK9 inhibitor targeting MYC-amplified solid tumors known as KB-0742.

NBTXR3 Injected in First Patient With Esophageal Cancer in Phase 1 Study

February 2nd 2021

In the phase 1 clinical trial of NBTXR3 with chemotherapy and radiation therapy as treatment of patients with esophageal cancer, the first patient has been dosed with the investigational tumor-agnostic radioenhancer.

Enzastaurin Dosed in First Phase 3 Study of Newly Diagnosed Glioblastoma Multiforme

January 11th 2021

The first patient with newly diagnosed glioblastoma multiforme has been dosed with the first-in-class small molecule enzastaurin in combination with temozolomide and radiotherapy in the phase 3 ENGAGE clinical trial with an aim of determining the overall survival outcome of the drug in this patient population.

Phase 3 Study Initiated to Explore Adjuvant Trastuzumab Deruxtecan in HER2+ Breast Cancer

November 10th 2020

A phase 3 study was initiated for a head-to-head comparison of trastuzumab deruxtecan versus T-DM1 as adjuvant treatment of a subset of patients with HER2-positive early breast cancer.

Pivotal Phase 3 Trial Initiated to Study Promising Cabozantinib/Atezolizumab Combo in Advanced RCC

July 22nd 2020

A pivotal phase 3 trial has been initiated to explore the combination of cabozantinib and atezolizumab for the treatment of patients with inoperable, locally advanced or metastatic renal cell carcinoma who progressed during or after treatment with an immune checkpoint inhibitor immediately following initial therapy.